Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-08-21
Goldsmith Mark A Files Revolution Medicines (RVMD) Form 4 - August 21, 2026
Goldsmith Mark A traded 166.0K RVMD shares worth $18.4M in this Form 4 filing, reported to the SEC on 2026-08-21.
- Insider
- Goldsmith Mark A
- Issuer
- Revolution Medicines Inc. RVMD · NASDAQ
- Filed
- Period
- 2026-08-21
- Accession
- 0001610717-26-000387
- Source
- Official filing on sec.gov ↗
Transactions (20)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Goldsmith Mark A | 2026-08-21 | Buy | 80.0K | $4.73 | $378.4K | Direct |
| Goldsmith Mark A | 2026-08-21 | Sell | 5.1K | $207.23 | $1.1M | Direct |
| Goldsmith Mark A | 2026-08-21 | Sell | 24.9K | $208.37 | $5.2M | Direct |
| Goldsmith Mark A | 2026-08-21 | Sell | 35.9K | $209.26 | $7.5M | Direct |
| Goldsmith Mark A | 2026-08-21 | Sell | 3.8K | $210.25 | $801.7K | Direct |
| Goldsmith Mark A | 2026-08-21 | Sell | 6.6K | $211.33 | $1.4M | Direct |
| Goldsmith Mark A | 2026-08-21 | Sell | 3.6K | $212.08 | $767.9K | Direct |
| Goldsmith Mark A | 2026-08-21 | Sell | 190 | $207.25 | $39.4K | Indirect |
| Goldsmith Mark A | 2026-08-21 | Sell | 951 | $208.36 | $198.2K | Indirect |
| Goldsmith Mark A | 2026-08-21 | Sell | 1.4K | $209.28 | $282.7K | Indirect |
| Goldsmith Mark A | 2026-08-21 | Sell | 136 | $210.40 | $28.6K | Indirect |
| Goldsmith Mark A | 2026-08-21 | Sell | 245 | $211.47 | $51.8K | Indirect |
| Goldsmith Mark A | 2026-08-21 | Sell | 127 | $212.06 | $26.9K | Indirect |
| Goldsmith Mark A | 2026-08-21 | Sell | 177 | $207.25 | $36.7K | Indirect |
| Goldsmith Mark A | 2026-08-21 | Sell | 937 | $208.36 | $195.2K | Indirect |
| Goldsmith Mark A | 2026-08-21 | Sell | 1.4K | $209.27 | $294.0K | Indirect |
| Goldsmith Mark A | 2026-08-21 | Sell | 126 | $210.40 | $26.5K | Indirect |
| Goldsmith Mark A | 2026-08-21 | Sell | 229 | $211.46 | $48.4K | Indirect |
| Goldsmith Mark A | 2026-08-21 | Sell | 126 | $212.06 | $26.7K | Indirect |
| Net change | −6.0K | −$17.6M | ||||
About Revolution Medicines Inc.
Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.
Track RVMD insider activity
Get alerted when Revolution Medicines Inc. executives buy or sell their shares.